Cencora Q3 2026 Call: Integration Costs and Buybacks Under Scrutiny

What happened

Cencora reported fiscal third-quarter 2026 results and held its earnings call, providing an update on key thesis drivers following the Q2 print that showed elevated integration costs and stalled buybacks. Management discussed OneOncology integration expenses, the trajectory of DS&A as a percentage of revenue, and progress toward the $1.0 billion repurchase target by calendar year-end. Commentary on manufacturer list-price deflation and customer mix shifts remains critical, as Q2 saw a $2 billion quarterly headwind and ongoing mail-order biosimilar pressure. The call likely addressed the impact of the CFO transition and any updates to fiscal 2026 guidance, previously raised to $17.70–$17.90. Early indicators from the transcript will determine whether the profit model is self-funding or if cost drags persist into year-end.

Implication

If the Q3 call confirms a decline in deal/integration expenses from $164 million and DS&A leverage improvement, the stock may approach the base-case $310 as the thesis strengthens. Failure to show margin resilience or credible repurchase execution shifts the risk-reward toward the bear case $250, as the OneOncology integration would appear more dilutive than accretive in the near term, and capital allocation discipline would be questioned. The WAIT rating is preserved until these data points are verified, but the Q3 print is the most important catalyst for re-assessment within the 3–6 month window.

Thesis delta

The thesis delta remains neutral until the Q3 call details are fully analyzed, as the master report’s WAIT rating was predicated on this event showing improvement in integration costs and buyback activity. If management fails to demonstrate progress on these fronts, the thesis shifts to a clear negative tilt, given the high expectations baked into the current multiple.